|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1999-4-23
|
|
pubmed:abstractText |
The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0039-2499
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
769-72
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10187877-Acute Disease,
pubmed-meshheading:10187877-Aged,
pubmed-meshheading:10187877-Cerebrovascular Disorders,
pubmed-meshheading:10187877-Disability Evaluation,
pubmed-meshheading:10187877-Double-Blind Method,
pubmed-meshheading:10187877-Female,
pubmed-meshheading:10187877-Hemiplegia,
pubmed-meshheading:10187877-Humans,
pubmed-meshheading:10187877-Intracranial Embolism and Thrombosis,
pubmed-meshheading:10187877-Logistic Models,
pubmed-meshheading:10187877-Male,
pubmed-meshheading:10187877-Middle Aged,
pubmed-meshheading:10187877-Neurologic Examination,
pubmed-meshheading:10187877-Plasminogen Activators,
pubmed-meshheading:10187877-Thrombolytic Therapy,
pubmed-meshheading:10187877-Tomography, X-Ray Computed,
pubmed-meshheading:10187877-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator.
|
|
pubmed:affiliation |
Department of Neuroradiology, University of Toulouse, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
